Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab (MEDI4736) and Tremelimumab in Muscle-invasive Urothelial Carcinoma

NCT03549715 is registered in ClinicalTrials.gov with Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie as lead sponsor.

NCT NCT03549715
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03549715 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab (MEDI4736) and Tremelimumab in Muscle-invasive Urothelial Carcinoma
Lead sponsor
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Phase
Phase 1/2
Overall status
Unknown status
Start date
December 6, 2018
Completion date
September 30, 2025
Enrollment
121 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

infiltrating bladder urothelial carcinoma